Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Second-generation inhibitors of Bruton tyrosine kinase.

Wu J, Liu C, Tsui ST, Liu D.

J Hematol Oncol. 2016 Sep 2;9(1):80. doi: 10.1186/s13045-016-0313-y. Review.

2.

Phosphoinositide 3-Kinase δ Regulates Dectin-2 Signaling and the Generation of Th2 and Th17 Immunity.

Lee MJ, Yoshimoto E, Saijo S, Iwakura Y, Lin X, Katz HR, Kanaoka Y, Barrett NA.

J Immunol. 2016 Jul 1;197(1):278-87. doi: 10.4049/jimmunol.1502485. Epub 2016 May 18.

PMID:
27194783
3.

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE 3rd, Butchar JP, Tridandapani S.

J Biol Chem. 2016 Feb 5;291(6):3043-52. doi: 10.1074/jbc.M115.687251. Epub 2015 Dec 1.

PMID:
26627823
4.

Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.

Kokabee L, Wang X, Sevinsky CJ, Wang WL, Cheu L, Chittur SV, Karimipoor M, Tenniswood M, Conklin DS.

Cancer Biol Ther. 2015;16(11):1604-15. doi: 10.1080/15384047.2015.1078023. Epub 2015 Sep 18.

5.

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia.

Wu H, Hu C, Wang A, Weisberg EL, Chen Y, Yun CH, Wang W, Liu Y, Liu X, Tian B, Wang J, Zhao Z, Liang Y, Li B, Wang L, Wang B, Chen C, Buhrlage SJ, Qi Z, Zou F, Nonami A, Li Y, Fernandes SM, Adamia S, Stone RM, Galinsky IA, Wang X, Yang G, Griffin JD, Brown JR, Eck MJ, Liu J, Gray NS, Liu Q.

Leukemia. 2016 Jan;30(1):173-81. doi: 10.1038/leu.2015.180. Epub 2015 Jul 13.

6.

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.

Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA, Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ.

Blood. 2015 Jul 2;126(1):61-8. doi: 10.1182/blood-2015-02-626846. Epub 2015 May 13.

7.

Internalization of B cell receptors in human EU12 μHC⁺ immature B cells specifically alters downstream signaling events.

Liu J, Xie W, Lange MD, Hong SY, Su K, Zhang Z.

Biomed Res Int. 2013;2013:807240. doi: 10.1155/2013/807240. Epub 2013 Oct 9.

8.

Identification of direct tyrosine kinase substrates based on protein kinase assay-linked phosphoproteomics.

Xue L, Geahlen RL, Tao WA.

Mol Cell Proteomics. 2013 Oct;12(10):2969-80. doi: 10.1074/mcp.O113.027722. Epub 2013 Jun 22.

9.

Novel Bruton's tyrosine kinase inhibitors currently in development.

D'Cruz OJ, Uckun FM.

Onco Targets Ther. 2013;6:161-76. doi: 10.2147/OTT.S33732. Epub 2013 Mar 6.

10.

The Dok-3/Grb2 protein signal module attenuates Lyn kinase-dependent activation of Syk kinase in B cell antigen receptor microclusters.

Lösing M, Goldbeck I, Manno B, Oellerich T, Schnyder T, Bohnenberger H, Stork B, Urlaub H, Batista FD, Wienands J, Engelke M.

J Biol Chem. 2013 Jan 25;288(4):2303-13. doi: 10.1074/jbc.M112.406546. Epub 2012 Dec 5.

11.

B cell-associated immune profiles in patients with end-stage renal disease (ESRD).

Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW, Kim YS, Cho SG, Cho ML, Yang CW.

Exp Mol Med. 2012 Aug 31;44(8):465-72. doi: 10.3858/emm.2012.44.8.053.

12.

The establishment of early B cell tolerance in humans: lessons from primary immunodeficiency diseases.

Meffre E.

Ann N Y Acad Sci. 2011 Dec;1246:1-10. doi: 10.1111/j.1749-6632.2011.06347.x. Review.

13.
14.

Defining the antigen receptor-dependent regulatory network that induces arrest of cycling immature B-lymphocytes.

Jamal MS, Ravichandran S, Jailkhani N, Chatterjee S, Dua R, Rao KV.

BMC Syst Biol. 2010 Dec 9;4:169. doi: 10.1186/1752-0509-4-169.

15.

Novel method for isolating untouched rat natural killer cells with higher purity compared with positive selection and fluorescence-activated cell sorting.

Poli A, Brons NH, Ammerlaan W, Michel T, Hentges F, Chekenya M, Zimmer J.

Immunology. 2010 Nov;131(3):386-94. doi: 10.1111/j.1365-2567.2010.03312.x.

16.

Ca2+ influx and protein scaffolding via TRPC3 sustain PKCbeta and ERK activation in B cells.

Numaga T, Nishida M, Kiyonaka S, Kato K, Katano M, Mori E, Kurosaki T, Inoue R, Hikida M, Putney JW Jr, Mori Y.

J Cell Sci. 2010 Mar 15;123(Pt 6):927-38. doi: 10.1242/jcs.061051. Epub 2010 Feb 23.

17.

Integration of a phosphatase cascade with the mitogen-activated protein kinase pathway provides for a novel signal processing function.

Chaudhri VK, Kumar D, Misra M, Dua R, Rao KV.

J Biol Chem. 2010 Jan 8;285(2):1296-310. doi: 10.1074/jbc.M109.055863. Epub 2009 Nov 6.

18.

B cell antigen receptor endocytosis and antigen presentation to T cells require Vav and dynamin.

Malhotra S, Kovats S, Zhang W, Coggeshall KM.

J Biol Chem. 2009 Sep 4;284(36):24088-97. doi: 10.1074/jbc.M109.014209. Epub 2009 Jul 8.

19.

BLNK binds active H-Ras to promote B cell receptor-mediated capping and ERK activation.

Imamura Y, Oda A, Katahira T, Bundo K, Pike KA, Ratcliffe MJ, Kitamura D.

J Biol Chem. 2009 Apr 10;284(15):9804-13. doi: 10.1074/jbc.M809051200. Epub 2009 Feb 13.

Items per page

Supplemental Content

Write to the Help Desk